Adenoid cystic carcinoma: Current therapy and potential therapeutic advances based on genomic profiling

Young Kwang Chae, Su Yun Chung, Andrew A. Davis, Benedito A. Carneiro, Sunandana Chandra, Jason Kaplan, Aparna Kalyan, Francis J. Giles

Research output: Contribution to journalArticlepeer-review

84 Scopus citations


Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Efficacy of current treatment options, particularly for advanced disease, is very limited. Recent whole genome and exome sequencing has dramatically improved our understanding of ACC pathogenesis. A balanced translocation resulting in the MYB-NFIB fusion gene appears to be a fundamental signature of ACC. In addition, sequencing has identified a number of other driver genes mutated in downstream pathways common to other well-studied cancers. Overexpression of oncogenic proteins involved in cell growth, adhesion, cell cycle regulation, and angiogenesis are also present in ACC. Collectively, studies have identified genes and proteins for targeted, mechanism-based, therapies based on tumor phenotypes, as opposed to nonspecific cytotoxic agents. In addition, although few studies in ACC currently exist, immunotherapy may also hold promise. Better genetic understanding will enable treatment with novel targeted agents and initial exploration of immune-based therapies with the goal of improving outcomes for patients with ACC.

Original languageEnglish
Pages (from-to)37117-37134
Number of pages18
Issue number35
StatePublished - 2015


  • Adenoid cystic carcinoma
  • Genetics
  • Immunotherapy
  • Targeted therapy


Dive into the research topics of 'Adenoid cystic carcinoma: Current therapy and potential therapeutic advances based on genomic profiling'. Together they form a unique fingerprint.

Cite this